J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025.
Short excerpt below. Click through to read at the original source.
Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.